PLRX Stock — Pliant Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$1.11

Market cap

$68.73M

Price action

19 metrics

Price change (1W)

-6.7%

Price change (30D)

+6.7%

Price change (3M)

-4.3%

Price change (6M)

-11.2%

Price change (YTD)

-9.0%

Price change (1Y)

-32.3%

Trailing year

Price change (5Y)

-93.9%

52-week high

$1.87

52-week low

$1.03

Change from 52-week high

-40.6%

Change from 52-week low

+7.8%

Annualized volatility

52.8%

Beta

1.0

RSI (14D)

49.5

Price vs SMA 50

+0.2%

Price vs SMA 200

-10.0%

Avg volume (3M)

507,561

Relative volume

0.5

Average dollar volume

$569,660

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

61.92M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

0.5

reciprocal yield 213.8%

FCF yield

-103.1%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-134.3%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

306.4×

reciprocal yield 0.3%

EV / revenue historical average (5Y)

306.4×

reciprocal yield 0.3%

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

—

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$97.48M

Net income (TTM)

−$92.29M

Trailing 12 months

Diluted EPS (TTM)

$-1.48

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-41.33

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

—

Revenue (TTM)

$0

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+0.9%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-62.8%

Return on assets

-48.6%

Debt / equity

0.0

Current ratio

9.9

EBITDA (TTM)

—

Free cash flow (TTM)

−$70.89M

Quick ratio

9.9

Interest coverage

-102.5

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$158.10M

Latest balance sheet

Cash & equivalents

$24.88M

Total assets

$189.88M

Total debt

$0

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$70.89M

Capital expenditures (TTM)

$0

R&D (TTM)

$63.83M

SG&A (TTM)

—

Stock compensation (TTM)

$19.38M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

86

13F filer change QoQ

-5

Institutional ownership

77.9%

Short interest

3 metrics

Short interest

4.5%

Latest settlement · 7.7 days to cover

Days to cover

7.7d

Short-squeeze score

63 / 100

Insider activity

2 metrics

Net insider buying (90D)

—

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

PLRX · Pliant Therapeutics, Inc.

PLRX metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search